The company exhibits critical financial distress, highlighted by a Piotroski F-Score of 0/9, indicating the weakest possible financial health. With a negative Price-to-Book ratio of -15.47 and a Current Ratio of 0.43, ONMD is facing a severe liquidity crisis and possesses negative shareholder equity. While the reported revenue growth of 3326.90% is astronomical, it is offset by a negative gross margin (-37.01%) and massive operating losses, suggesting that growth is currently being achieved at an unsustainable cost. The combination of bearish insider activity and a total lack of profitability makes this a high-risk speculative asset.